Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01773187
Recruitment Status : Terminated
First Posted : January 23, 2013
Last Update Posted : October 22, 2018
Sponsor:
Information provided by (Responsible Party):
CTI BioPharma

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : January 2015
Actual Study Completion Date : June 2016
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 December 11, 2018
(Canceled on December 19, 2018)